PLSE Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
395.0K
-9.0%
434.0K
+8.2%
401.0K
+51.9%
264.0K
+207.0%
86.0K
Cost of Revenue
191.0K
-30.0%
273.0K
-26.2%
370.0K
+42.3%
260.0K
-6.8%
279.0K
Gross Profit
204.0K
+26.7%
161.0K
+419.4%
31.0K
+675.0%
4.0K
+102.1%
-193000
Operating Expenses
24.5M
-3.7%
25.4M
+32.6%
19.2M
+5.1%
18.3M
-9.5%
20.2M
R&D
16.8M
-0.8%
17.0M
+34.8%
12.6M
+15.2%
10.9M
-4.1%
11.4M
SG&A
7.6M
-9.6%
8.5M
+28.3%
6.6M
-10.1%
7.3M
-16.5%
8.8M
Operating Income
-24292000
+3.9%
-25272000
-32.0%
-19150000
-4.9%
-18253000
+10.4%
-20367000
EBITDA
-24031000
+3.9%
-25018000
-32.4%
-18895000
-5.0%
-17994000
+10.5%
-20111000
Net Income
-23051000
+6.5%
-24657000
-32.7%
-18581000
-6.6%
-17433000
+10.1%
-19385000
EPS (Basic)
$-0.32
+11.1%
$-0.36
-33.3%
$-0.27
-3.8%
$-0.26
+10.3%
$-0.29
EPS (Diluted)
$-0.32
+11.1%
$-0.36
-33.3%
$-0.27
-3.8%
$-0.26
+10.3%
$-0.29
Shares (Diluted)
71.9M
+3.9%
69.2M
+1.8%
68.0M
+0.3%
67.8M
+0.6%
67.4M
Pulse Biosciences, Inc (DE) (PLSE) — Financials